Metastatic prostate carcinoma

This study tested whether taking the drug abiraterone on an on-and-off schedule could help it work longer for men with advanced prostate cancer that no longer responds to hormone therapy. Nineteen men whose cancer had already responded to standard daily abiraterone were enrolled.…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer worsening in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to men from an earlier study wh…

This study tested a radioactive drug called 177Lu-PSMA-617 in 62 Chinese men with advanced prostate cancer that had spread and stopped responding to hormone therapy and chemotherapy. The drug targets a protein on cancer cells and delivers radiation directly to them. Researchers m…

This study tests a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The trial aims to find the safest effective dose and see if it can lo…

Researchers are testing whether giving radiation therapy before sipuleucel-T, a personalized immunotherapy vaccine, works better than the vaccine alone in men with hormone-resistant prostate cancer that has spread. The trial enrolls about 51 participants and randomly assigns them…

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early …

This phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen…

This phase 2 trial is testing whether surgery and radiation can help men whose prostate cancer has come back and spread to a few spots in the body. About 20 participants will receive either surgery to remove the spread tumors or targeted radiation, or both. The main goal is to se…

This study tested whether adding the drug niraparib to standard radiation and hormone therapy can help prevent high-risk prostate cancer from coming back. Niraparib blocks a protein that cancer cells use to repair their DNA, which may kill them. The trial enrolled 22 men with agg…

This study tests whether combining the immunotherapy drug ipilimumab with the hormone therapy degarelix, given before and after prostate removal surgery, can control advanced prostate cancer. It includes two groups: men with newly diagnosed cancer that has spread to a few other s…

This phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced urinary tract cancer live longer. 506 patients with cancer that had spread or could not be removed by surgery took part. The study compar…

This study tested the safety and effectiveness of enzalutamide (Xtandi) in 52 Indian men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy. Participants took enzalutamide daily while continuing hormone therapy. The main goal was to see how …

This completed phase II trial tested whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that no longer responds to hormone therapy. Nineteen men with metastatic castration-res…

This early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combination can shrink or eliminate tumo…

This phase 2 trial tested the chemotherapy drug carboplatin in 16 men with metastatic castration-resistant prostate cancer that has specific gene changes in the homologous recombination pathway. The goal was to see if carboplatin could shrink tumors or lower PSA levels. The study…

This study tested a combination of two targeted drugs (pertuzumab and trastuzumab) plus a chemotherapy drug (enzalutamide) in 7 men with advanced prostate cancer that had stopped responding to standard treatments. The goal was to see if the combination could shrink or slow the gr…

This phase II trial tested a combination of three drugs—carboplatin, cabazitaxel, and abiraterone—in 61 men with high-volume metastatic prostate cancer that still responds to hormone therapy. The goal was to see how many men had no cancer growth after one year. The study also tra…

This study tests whether adding an immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with a tough-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men with metastatic castration-resistant prostate c…

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This trial tested whether a precise type of radiation called SBRT could slow the growth of metastatic prostate cancer in men whose disease was starting to worsen despite hormone therapy. 86 men with one or two growing tumors received SBRT while continuing their current hormone dr…

This study tested a radioactive drug called 177Lu-PSMA-617 in 94 Japanese men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers measured how well it shrank tumor…

This early-stage trial tested the safety and best dose of adding niclosamide (a drug used for tapeworm infections) to standard hormone therapy (enzalutamide) in 6 men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combinatio…

This Phase 2 trial tested an immunotherapy drug called vudalimab, either by itself or combined with standard chemotherapy or targeted therapy, in 72 men with metastatic castration-resistant prostate cancer that had worsened after prior treatments. The main goal was to check safet…

This early-stage study tested a new drug, ARV-110, combined with the standard treatment abiraterone in 45 men with metastatic prostate cancer whose PSA levels were rising despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete,…

This study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. …

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This early-phase study tested a new drug, opevesostat (MK-5684), in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. This is a first step to se…

This large Phase 3 trial tested whether adding the immunotherapy pembrolizumab (Keytruda) to standard hormone therapy (enzalutamide plus ADT) could improve outcomes for men with metastatic hormone-sensitive prostate cancer. Over 1,200 participants were enrolled. The study was unb…

This early-phase trial tested a combination of four drugs—apalutamide, abiraterone, docetaxel, and prednisone—in 16 men with metastatic castrate-resistant prostate cancer, a form of the disease that no longer responds to standard hormone therapy. The main goal was to find a safe …

This early-phase study tested a new treatment called JNJ-75229414, which uses a patient's own immune cells (T cells) engineered to attack prostate cancer cells. The study involved 15 men with metastatic castration-resistant prostate cancer that had already been treated with other…

This study tested whether giving two drugs together—Radium-223 and enzalutamide—is safe for men with advanced prostate cancer that has spread to other parts of the body and is no longer controlled by standard hormone therapy. 45 men took part. The main goal was to track serious s…

This early-phase study tested a new combination of two drugs—enzalutamide and relacorilant—in 42 men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check safety and see how the drugs interact in the body. Researchers also…

This early-phase study tested a new drug called MK-5684 (opevesostat) in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. Participants took the…

This study tested whether adding the drug axitinib to standard hormone therapy before surgery helps men with prostate cancer that has spread to lymph nodes. About 73 men received either hormone therapy alone or hormone therapy plus axitinib before having their prostate removed. T…

This early-phase trial tested an experimental cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest and most effective dose by measuring immune cell activity, PSA levels, and tumor changes. …

This phase 2 trial tested a drug called Lutetium-177-PSMA-617, which delivers radiation directly to prostate cancer cells. It included 58 men with prostate cancer that had spread to a few spots in bones or lymph nodes but was still hormone-sensitive. The study compared the drug t…

This study tested whether adding darolutamide to standard hormone therapy helps men with prostate cancer that has spread to other parts of the body. 669 men participated. The goal was to see if the combination delays cancer growth or death. Results showed improvement in progressi…

This early-phase study tested a new drug called JNJ-70218902 in 82 people with advanced solid tumors, including prostate cancer. The drug works by redirecting the body's immune T cells to attack cancer cells. The main goals were to find a safe dose and check for side effects, not…

This study looked at whether men with advanced prostate cancer could safely stop their regular hormone injections (like leuprolide) and rely only on the pills abiraterone and prednisone to keep testosterone at very low levels. 31 men participated. The goal was to see if testoster…

This study tested whether adding a precise, high-dose radiation treatment (SBRT) to the hormone therapy apalutamide helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. Twenty-six men with this type of cancer took part. …

This phase 2 trial tested two immunotherapy drugs, ipilimumab and nivolumab, in 69 men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants…

This study tested whether adding the drug TAK-700 to standard hormone therapy helps men with newly diagnosed prostate cancer that has spread live longer than adding the drug bicalutamide. Over 1,300 men took part. The goal was to see which combination works better for controlling…

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors or slow progression in men with metastatic castration-resistant prostate cancer. 351 participants received either the combination, ipilimumab alone, or the chemother…

This early-stage trial tested a new drug called CC-94676 in 131 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to standard hormone therapy. The main goal was to check safety and find the right dose, while also looking for signs that t…

This study tested a drug called niraparib in 289 men with advanced prostate cancer that no longer responds to hormone therapy and has specific DNA repair issues. The goal was to see if the drug could shrink tumors or slow the disease. Results may help identify which patients coul…

This study tested whether adding a radioactive drug (Radium-223) to targeted radiation (SABR) helps men with prostate cancer that has spread to a few bones or soft tissues. 64 men participated, receiving either SABR alone or SABR plus Radium-223. The goal was to see if the combin…

This large phase 3 trial tested whether adding the chemotherapy drug docetaxel to standard hormone therapy helps men with metastatic prostate cancer live longer. 790 men participated. The results showed that the combination improved overall survival compared to hormone therapy al…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) — alone or with an injected immune stimulant called SD-101 — to standard radiation and short-term hormone therapy could better control prostate cancer that has spread to a few spots. Twenty-three men…

This Phase 3 study tested whether adding darolutamide to standard hormone therapy and chemotherapy helps men with metastatic hormone-sensitive prostate cancer live longer. Over 1,300 participants received either darolutamide or a placebo, along with standard treatments. The main …

This early-phase trial tested a combination of three drugs—cabozantinib, abiraterone, and nivolumab—in 18 men with metastatic hormone-sensitive prostate cancer that had not yet been treated. The main goal was to find a safe dose and check for serious side effects. Researchers als…

This study tested an experimental drug called CPI-1205 combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in 175 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and stopped responding to usual horm…

This phase 3 study tested the drug enzalutamide in 395 Asian men with metastatic prostate cancer that had stopped responding to standard hormone therapy. Participants had not yet received chemotherapy. The study compared enzalutamide to a placebo to see if it could delay rises in…

This large phase 3 trial tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps men with metastatic hormone-sensitive prostate cancer. Over 1,100 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how lo…

This study looked at whether giving chemotherapy (docetaxel) before starting hormone therapy (degarelix) helps men with prostate cancer that has spread. 52 men took part. The main goal was to see how many had very low PSA levels after 10 months. The approach aims to improve disea…

This phase 2 trial tested whether adding a radioactive drug (I-131-1095) to standard enzalutamide therapy helps men with a specific type of advanced prostate cancer that had worsened on another treatment. The study enrolled 120 men with PSMA-positive metastatic castration-resista…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This early-phase trial tested a combination of two drugs—docetaxel (a chemotherapy) and radium 223 (a radioactive drug)—in 43 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goal was to find the safest dose and wa…

This study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to fo…

This study tested a two-step treatment in 15 men with metastatic castration-resistant prostate cancer. First, they took high-dose oral testosterone for three 28-day cycles. If the cancer grew, they switched to enzalutamide. The goal was to see if oral testosterone could control t…

This study tested a combination of two drugs, apalutamide and abiraterone, plus prednisone, in 93 men with advanced prostate cancer that had spread and was no longer responding to hormone therapy. The goal was to see how long the cancer stayed under control and whether the drugs …

This study tested a single injection of triptorelin pamoate that lasts 6 months in 195 Chinese men with advanced or metastatic prostate cancer. The goal was to lower testosterone to castrate levels, which helps slow cancer growth. Results showed the injection effectively reduced …

This study looked at men with advanced prostate cancer that no longer responds to hormone therapy. When the standard dose of abiraterone stopped working, some patients received a double dose to see if it could stabilize the disease. The goal was to find out if this approach is sa…

This study tests a special dye that makes prostate cancer cells glow during surgery. About 22 men with aggressive prostate cancer will receive the dye before their prostate removal surgery. Surgeons will use a special camera to see the glowing cancer, helping them remove more of …

This study tested a new type of PET scan using a radioactive tracer called 89Zr-DFO-huJ591 to find prostate cancer that has spread to other parts of the body. 77 men with metastatic prostate cancer received the experimental scan, and some also had standard scans and biopsies for …

This study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and to measure how much radiation the body receives. The agent helps doctors see where cancer has spread using a special scan.

This pilot study tested whether a special PET scan (18F-fluciclovine) can better track how advanced prostate cancer responds to treatment compared to standard CT and bone scans. Nine men with metastatic castration-resistant prostate cancer received the scan before and 12 weeks af…

This study tested whether tadalafil, a drug often used for erectile dysfunction, can prevent nerve damage caused by docetaxel chemotherapy in men with metastatic prostate cancer. 90 participants were randomly assigned to receive either tadalafil plus standard care or standard car…

This study tests whether a personalized 4-week exercise program can improve quality of life and physical function in men with metastatic prostate cancer who are receiving radiation therapy. Eighty participants will either exercise or not, and researchers will track changes in wel…

This study tests whether a 12-week, drug-free exercise program can help men with metastatic prostate cancer who are starting hormone therapy. The program includes supervised sessions of aerobic, resistance, balance, and flexibility exercises. The main goal is to see if patients c…

This study tested whether using virtual reality hypnosis before chemotherapy infusions could lower anxiety in men with metastatic prostate cancer. Fifty-three patients were randomly assigned to either receive the VR hypnosis session or standard care before each docetaxel infusion…

This study looked at whether men with metastatic prostate cancer prefer cabazitaxel or docetaxel as their first chemotherapy. 195 patients tried both drugs in sequence and then stated their preference. The goal is to see if side effects like nerve damage or fatigue influence choi…

This study tested whether exercise, with or without internet-based cognitive behavior therapy, could reduce fatigue in 126 men with advanced prostate cancer. Participants were on hormone therapy and followed a 12-week exercise program. The goal was to see if these non-drug approa…

This completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and q…

This study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug caus…

This study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that …

This study follows about 500 men with advanced prostate cancer that still responds to hormone therapy. Researchers are comparing two drug combinations (apalutamide or enzalutamide plus standard hormone therapy) to see how well they work in real-world settings. The goal is to unde…

This study tested whether Pluvicto, a radioactive drug for prostate cancer, can be safely given through a permanently implanted port (TIVAP) instead of a standard IV. Researchers measured if any drug got stuck in the port in 107 patients. The goal was to see if using the port is …

This completed study looked at 80 patients with advanced prostate cancer that had stopped responding to chemotherapy. All patients received a radioactive drug called 177Lu-PSMA-617. Researchers compared two types of scans—PET and SPECT—to see which better tracks changes in tumor …

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…

This study created a massive, secure database of over 14,000 prostate MRI scans from men with or suspected of having prostate cancer. Researchers used this data to train artificial intelligence (AI) models to better tell apart slow-growing from aggressive cancers, predict if canc…

This early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identi…

This study tested whether taking dasatinib alone or with darolutamide for 14 days can increase PSMA levels on PET scans in men with metastatic prostate cancer. Only 4 men participated, all with low PSMA uptake on their initial scan. The goal was to learn more about how PSMA expre…

This study looked at whether an educational session about orchiectomy (surgery to remove the testicles) would make more men with prostate cancer choose it over lifelong hormone therapy. 101 men who were already on hormone therapy for at least a year took part. The goal was to see…

This study looked at 168 men with metastatic hormone-sensitive prostate cancer to see if a model using PSMA-PET scans and routine medical information could predict how well they would respond to standard first-line treatment. The goal was to help doctors better understand which p…

This study looked at over 1,200 men with advanced prostate cancer who received a radioactive drug called Lutetium-177 vipivotide tetraxetan in real-world clinics. Researchers tracked patient characteristics, treatment patterns, and PSA level reductions. The goal was to see how th…

This study examined medical records of over 6,400 prostate cancer patients who received a treatment called 177Lu-PSMA-617. Researchers wanted to understand the patients' characteristics, treatment patterns, and survival outcomes. The study did not test a new treatment but instead…

This study looked at medical records from over 2,700 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers compared two common treatments, enzalutamide and abiraterone, to see which one helped men live longer. The goal was to understand how the…

This study tested a new education program for men with metastatic prostate cancer who are taking next-generation hormone therapy. The program aimed to help patients better understand their disease, stick to their medication, and improve their quality of life. 18 patients took par…

This study analyzed blood samples from 33 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers looked for tiny molecules called microRNAs that might predict whether a patient will resist chemotherapy or newer hormone drugs. The goal is to help…

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This completed study looked at over 1,000 men with metastatic prostate cancer in the Pirkanmaa region of Finland. Researchers analyzed patient characteristics, treatments used, and outcomes to better understand the disease burden. The goal was to fill gaps in knowledge about how …

This completed study examined how long men with metastatic castration-sensitive prostate cancer take newer hormonal therapies like abiraterone, apalutamide, and enzalutamide. Researchers analyzed Medicare claims data from over 3,000 men aged 65 and older. The goal was to describe…

This completed registry study followed nearly 1,000 Japanese men with high-risk metastatic hormone-naïve prostate cancer to see how well standard treatments work in everyday medical practice. Researchers tracked PSA levels, cancer progression, survival, and quality of life. No ne…

This study reviewed medical records from over 1,300 men with metastatic prostate cancer that still responds to hormone therapy. Researchers wanted to see how long patients actually take the pills apalutamide or enzalutamide when prescribed by their own doctors in routine care. Th…

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…

This study tested a mobile-friendly web tool that educates men with prostate cancer about genetic testing. Researchers compared traditional genetic counseling with the online tool to see if it helps patients decide whether to get tested. The study involved 346 men with advanced o…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study followed over 1,400 men with metastatic castration-resistant prostate cancer who were already receiving Radium-223 as part of their routine care. Researchers tracked serious side effects and the development of new cancers over several years. The goal was to better unde…

This study looked at how the drug radium-223 spreads in the bones of men with prostate cancer that has spread to bones. Researchers gave the drug intravenously every 4 weeks for up to 6 doses and used imaging scans to measure its distribution in both tumor and healthy bone. The g…